We welcomed students from the Ewha Womans University in Korea through its “Pharm Challenger Project” – an opportunity for students to visit organizations researching new areas of medicine. For their project, these women are eagerly exploring the world of targeted protein degradation, researching the current state of the field and its potential to impact patients. Our team had a fantastic day with the students, guiding them through our #TPD approach and mission to create a new way to treat diseases like cancer. As we celebrate International Day of Women and Girls in Science, hear from our vice president of clinical pharmacology, Eunju Hurh, about the impact of helping young scientists learn more about the many different areas of therapeutic development. #February11 #WomenInScience #IDWGS
C4 Therapeutics, Inc.
生物技术
Watertown,MA 16,001 位关注者
Clinical-stage biotech company transforming how disease is treated through targeted protein degradation science
关于我们
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes.
- 网站
-
http://www.c4therapeutics.com
C4 Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术
- 规模
- 51-200 人
- 总部
- Watertown,MA
- 类型
- 上市公司
- 创立
- 2015
- 领域
- biotechnology、cell biology、protein chemistry、cell pharmacology和Protein Degradation
地点
-
主要
490 Arsenal Way
Suite #120
US,MA,Watertown,02472
C4 Therapeutics, Inc.员工
动态
-
Transforming a patient’s treatment experience is one of the driving factors of our work to create a new generation of #TPD medicines. Treatment resistance is a defining challenge in our disease areas of focus, including multiple myeloma and BRAF V600 mutant cancers. Learn about our approach to treating cancer by degrading disease-causing proteins to potentially prevent new mutations that cause treatment resistance. https://bit.ly/3Q1804k #WorldCancerDay #cancerresearch #cancer #myeloma #lymphoma #CRC #melanoma
-
Have you visited our Scientific Presentations & Publications page? Check it out to view past presentations from industry events and learn about progress across our discovery platform and clinical programs: https://bit.ly/405hAYS #TPD #biotech
-
-
Learn about cancers with BRAF mutations – the target of our CFT1946 program, an orally bioavailable BiDAC™ degrader of BRAF V600 mutations. CFT1946 is currently being studied in a Phase 1/2 clinical trial in patients with BRAF V600 mutant solid tumors. BRAF V600 mutations are found in cancers including melanoma and colorectal cancer (CRC). Visit our website for more: https://bit.ly/43ygxPi
-
-
Martin Luther King Jr.’s message of having integrity and empathy for others is a reminder of why we contribute to our community, support our colleagues and are driven to develop medicines that transform lives. #MLKDay
-
The spark that ignited the field of #TPD began in 1999 with a realization that disease-causing proteins could be tagged by E3 ligases and destroyed by the proteasome. Since then, clinical progress has opened a new path for targeting previously undruggable proteins driving cancer, inflammation, and neurodegeneration. Check out this article in Chemistry World for a detailed history on our field, including insights from our chief scientific officer Paige Mahaney on the vast potential for new TPD treatments to transform patients’ lives.
Every cell in your body contains ‘molecular shredders’. The proteasome has evolved to tear up proteins tagged by other enzymes. But what if we could tag invasive or cancerous proteins?
-
We announced anticipated milestones for 2025 as we advance our clinical portfolio of orally bioavailable #degrader medicines targeting cancers with high unmet needs. Read more in our latest press release: https://bit.ly/3DNnNzJ #TPD
-
We will present at the J.P. Morgan 43rd Annual Healthcare Conference on Wednesday, January 15 at 2:15 p.m. PST in San Francisco. Learn more in our latest release: https://bit.ly/4gH713S #TPD #biotech #JPM25
-
-
Our annual holiday shutdown begins soon, an opportunity to reflect on the impactful and momentous year we’ve had and refresh ourselves for all that is to come in the new year. Wishing the #C4TxTeam, our partners and community a happy holiday – we’ll see you in 2025!
-
-
2024 was a transformative year for the #C4Txteam, one that elevated our discovery and clinical initiatives, welcomed new leaders to guide our progress and heightened our momentum to deliver transformative progress through targeted protein degradation (#TPD) science. Along the way we launched a new discovery partnership with Merck KGaA, Darmstadt, Germany, saw our CFT8919 program reach the clinic alongside Betta Pharmaceuticals Co., Ltd. , shared findings from our cemsidomide and CFT1946 clinical trials, were recognized by the BostInno Fire Awards and Boston Globe Media's Top Places to Work and so much more. We’re thrilled to see all that’s to come in the new year!